西班牙肺癌组（SLCG）进行了一项研究，分析了在西班牙的临床实践中，对非小细胞肺癌（NSCLC）中创新靶向疗法的接触障碍。查阅欧洲委员会、欧洲药品管理局和西班牙药品和医疗产品机构网站上的所有相关内容，了解肿瘤治疗的授权和接触情况。有超过20种靶向疗法可用于治疗不同的NSCLC患者的分子改变。欧洲委员会已批准了涉及以下基因的基因组改变的治疗方法：ALK、RET、ROS1、EGFR、BRAF、NTRK、KRAS、MET。然而，这些治疗方法在西班牙的可及性并不完全，创新治疗方法没有得到报销或者推迟，目前只有这些改变中的五种在国家卫生系统的范围内覆盖。SLCG认为，改善西班牙对NSCLC创新治疗的接触至关重要，以减少欧洲国家间的不平等。© 2023. 作者（们）。

Spanish Lung Cancer Group (SLCG) conducted a review to analyze the barriers to access to innovative targeted therapies for non-small cell lung cancer (NSCLC) in clinical practice in Spain.Review all relevant content published on websites of European Commission, European Medicines Agency, and Spanish Agency of Medicines and Medical Products regarding the authorization and access to oncology treatments.More than 20 targeted therapies are available to treat different molecular alterations in patients with NSCLC. European Commission has approved treatments for genomic alterations involving the following genes: ALK, RET, ROS1, EGFR, BRAF, NTRK, KRAS, MET. However, the availability of these therapies in Spain is not complete, as innovative treatments are not reimbursed or funded late, with only five of these alterations currently covered by National Health System.SLCG considers imperative to improve the access in Spain to innovative treatments for NSCLC to reduce inequity across European countries.© 2023. The Author(s).